Understanding Migraine in Community Pharmacy
Programme Terms and Conditions: commissioned and funded by AbbVie Ltd
Important: please read before you register.
This programme has been developed by CliniLink Ltd and is commissioned and funded by AbbVie Ltd. It contains promotional content and information about AbbVie medicines and is intended for UK registered healthcare professionals only.
If you register for this programme, the personal data you provide and information about your participation, including your enrolment, progress, completion status and completion rates, assessment results and certificates, will be shared with AbbVie Ltd. Sharing this data is a condition of taking part. Full details are set out in section 7.
These Programme Terms apply to the Understanding Migraine in Community Pharmacy programme (the "Programme") delivered through the CliniLink Academy Partner Hub. They should be read alongside the CliniLink Academy Terms and Conditions, our Privacy Policy and our Cookie Policy.
1. About these Programme Terms
1.1The Programme is delivered by CliniLink Ltd ("CliniLink", "we", "us", "our"), a company registered in England and Wales under company number 16243215, whose registered office is at Stockport Pyramid, Yew Street, Stockport Trading Estate, Stockport, SK4 2JZ. ICO Registration Number: ZB896601.
1.2The Programme is commissioned and funded by AbbVie Ltd ("AbbVie"), a company registered in England and Wales under company number 08004972, whose registered office is at AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB.
1.3Where these Programme Terms differ from the CliniLink Academy Terms and Conditions, these Programme Terms take priority for everything relating to the Programme. In all other respects the CliniLink Academy Terms and Conditions continue to apply.
1.4By ticking the registration declaration in section 7.12 and completing registration, you confirm that you have read and agree to these Programme Terms. If you do not agree, please do not register for the Programme.
2. The Programme and the Involvement of AbbVie
2.1The Programme consists of three e-learning modules on headache and migraine for pharmacy and primary care professionals. Modules will be released in stages and will be shown in the Partner Hub as "coming soon" until they are available.
2.2In line with the ABPI Code of Practice for the Pharmaceutical Industry, we declare the following:
- Developed by: co-created by CliniLink Ltd and AbbVie Ltd.
- Commissioned and funded by: AbbVie Ltd.
- Role of AbbVie: AbbVie co-created the Programme content with CliniLink and has reviewed and certified the Programme content and the materials used to promote it.
- Nature of the activity: the Programme is promotional and contains information about AQUIPTA® ▼ (atogepant).
- Prescribing information and adverse event reporting: AQUIPTA® ▼ (atogepant) prescribing information is available on each relevant page of the Programme. Adverse event reporting information is set out in section 9.
2.3The Programme is provided free of charge. Access to it is not offered, and must not be taken, as an inducement to prescribe, supply, recommend, buy or sell any medicine. You are under no obligation to AbbVie or to CliniLink as a result of taking part.
3. Eligibility and Professional Verification
3.1The Programme is available only to healthcare professionals currently registered with a UK professional regulator, including the General Pharmaceutical Council (GPhC). It is not intended for members of the public, students who are not yet registered, or healthcare professionals practising outside the United Kingdom.
3.2As part of registration you must provide your professional registration number. We verify this against the public register before you are enrolled. If we cannot verify your registration, you will not be given access to the Programme.
3.3You must tell us promptly if your registration lapses, is suspended or is subject to conditions that affect your practice. We may withdraw access to the Programme if you no longer meet the eligibility requirements.
3.4You must be at least 18 years of age to register.
4. Your Account and the Partner Hub
4.1Learners who join through the AbbVie invitation link are enrolled into the CliniLink Academy Partner Hub, a dedicated learning environment for this Programme. The Partner Hub does not show other CliniLink courses or products.
4.2If you already hold a CliniLink Academy account and join the Programme through a CliniLink link, you keep your existing account and access. Section 7 applies to your Programme activity only and does not cover your activity on other CliniLink courses.
4.3Your account is personal to you. You must not share your login details or allow any other person to complete Programme modules or assessments on your behalf.
5. Programme Content
5.1Programme content is provided for educational purposes only. It does not replace the Summary of Product Characteristics for any medicine, national or local guidance, or your own professional judgement.
5.2We take reasonable care to ensure content is accurate and up to date at the date of preparation shown on each module. Clinical evidence and product licences change, and you remain responsible for checking current guidance and prescribing information before acting on any content.
5.3We and AbbVie may update, withdraw or replace Programme content at any time, including where required by the ABPI Code of Practice, a change in a product licence or new safety information.
6. CPD Certificates
6.1On successful completion of each eligible module you will receive a CPD certificate in your registered name, which may include your professional registration number.
6.2Certificates evidence completion of the learning activity only. They do not confer any qualification, licence or competence to prescribe or supply any medicine.
7. Sharing Your Data with AbbVie
7.1Sharing is a condition of taking part. Because AbbVie commissions and funds the Programme, AbbVie requires information about who takes part and how the Programme is used. By registering, you acknowledge that we will share the personal data described in this section with AbbVie.
7.2What we share. We will share the following information with AbbVie:
| Category | Information shared |
|---|---|
| Identity and contact | Your full name and email address |
| Professional details | Your profession, professional regulator, registration number and verification status, job role, practice setting, organisation and region |
| Enrolment | Date of registration, the route by which you joined, and the modules you are enrolled on |
| Progress and completion | Module start and completion dates, progress through each module, completion status and completion rates |
| Assessment | Pre and post module assessment scores, pass or fail results and number of attempts |
| Certificates | CPD certificates issued and the date of issue |
| Feedback | Your answers to Programme evaluation and feedback surveys |
| Communication preferences | Whether you have given or withdrawn the permissions described in section 8 |
7.3What we do not share. We do not share your password, payment details, your activity on any other CliniLink course or event, or any information unrelated to the Programme.
7.4How AbbVie may use your data. AbbVie may use the shared data only to:
- monitor the reach, uptake, completion and educational outcomes of the Programme;
- evaluate the quality and effectiveness of the Programme and plan future educational activity;
- confirm that the Programme was delivered to an eligible audience of UK registered healthcare professionals, as required by the ABPI Code of Practice;
- meet its legal, regulatory, audit and pharmacovigilance obligations, including following up any adverse event or product complaint you report; and
- contact you about the Programme or AbbVie medicines only where you have given separate permission under section 8.
7.5What AbbVie will not do. AbbVie will not sell your data, will not use your Programme participation or assessment results to assess or reward your prescribing, and will not send you promotional emails, calls or visits on the basis of this data sharing alone.
7.6Who is responsible for your data. CliniLink Ltd is the data controller for your data while it is processed on the CliniLink Academy platform. Once your data has been shared, AbbVie Ltd is an independent data controller for the data it receives and is responsible for its own use of that data in line with the AbbVie Privacy Notice.
7.7Lawful basis. We share your data with AbbVie on the basis of the legitimate interests of CliniLink and AbbVie in delivering, evaluating, reporting on and demonstrating the compliance of a funded education programme (UK GDPR Article 6(1)(f)). We have assessed that these interests are not overridden by your rights, because the sharing is limited to Programme data, is explained to you in full before you register, and is restricted to the purposes in section 7.4. Communications under section 8 rely on your separate consent.
7.8How data is transferred. Data is shared with AbbVie by secure, encrypted transfer at agreed intervals during the Programme and at its close. AbbVie is part of a global group, and AbbVie may transfer your data outside the United Kingdom. Where it does so, AbbVie is responsible for ensuring appropriate safeguards are in place, such as the UK International Data Transfer Agreement or Addendum.
7.9How long data is kept. CliniLink keeps Programme records for the duration of the Programme and for six years afterwards, so that we can support CPD records and meet our contractual and audit obligations. AbbVie keeps the data it receives in line with its own retention schedule, as set out in the AbbVie Privacy Notice.
7.10Your rights. You have the right to access, correct and request deletion of your data, to object to its processing and to complain to the Information Commissioner's Office (ico.org.uk). For data held by CliniLink, contact us using the details in section 17. For data already shared with AbbVie, you can contact AbbVie through its privacy enquiry form at abbvie.com/privacy-inquiry. If you object to sharing, we will stop sharing your data from that point, although this may mean you can no longer take part in the Programme.
7.11If you do not want your data shared. Please do not register for the Programme. You can contact us at [email protected] to ask about other CliniLink learning that is not funded by a pharmaceutical company.
7.12Registration declaration. At registration you will be asked to tick the following mandatory declaration:
8. Communications
8.1Service emails. We will send you emails needed to deliver the Programme, such as enrolment confirmation, module release notices, reminders to complete modules and certificate emails. These contain no promotional content.
8.2Emails about pharmaceutical company funded programmes. We will send you other emails about educational programmes funded by pharmaceutical companies only if you give separate permission using the optional, unticked tick box described in section 7 of the CliniLink Academy Terms and Conditions.
8.3Direct contact from AbbVie. AbbVie will contact you directly about its medicines or services only if you tick the following separate, optional box. Ticking it is not required to take part in the Programme:
8.4Each permission decision is recorded with the date, the wording version and the point of capture, and is shared with AbbVie under section 7.2. You can withdraw any permission at any time by using the unsubscribe link in any email or by contacting us or AbbVie.
9. Adverse Event Reporting
9.1Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app. Adverse events should also be reported to AbbVie at [email protected].
9.2If you tell CliniLink about an adverse event or product complaint relating to an AbbVie medicine during the Programme, for example in a feedback form or email, we are required to pass it to AbbVie within one working day, together with your contact details so that AbbVie can follow it up.
10. Independence and Professional Conduct
10.1Your decisions about the care of your patients must be based on clinical need, the evidence and current guidance, and must remain independent of your participation in the Programme.
10.2Nothing in the Programme constitutes a request or expectation that you prescribe, supply, recommend or purchase any AbbVie medicine.
11. Intellectual Property
11.1All Programme content is owned by, or licensed to, CliniLink Ltd and AbbVie Ltd. We grant you a personal, non transferable, non exclusive licence to access the content for your own professional development.
11.2You must not copy, download, record, share, publish or distribute Programme content, including with members of the public, without our prior written permission.
12. Acceptable Use
12.1You must not use the Programme in any way that is unlawful, misleading or that infringes the rights of others, and you must not attempt to gain unauthorised access to any part of the platform or to other accounts.
12.2Providing false registration or professional details is a breach of these Programme Terms and may be reported to your professional regulator where appropriate.
13. Liability
13.1Nothing in these Programme Terms limits or excludes liability for death or personal injury caused by negligence, for fraud or for any other liability that cannot be limited or excluded by law.
13.2Subject to clause 13.1, neither CliniLink nor AbbVie is liable for any loss or damage arising from your reliance on Programme content in place of your own professional judgement, current prescribing information or guidance.
14. Withdrawal, Suspension and End of the Programme
14.1You may withdraw from the Programme at any time by contacting us. Data shared with AbbVie before you withdraw will remain with AbbVie and be handled under the AbbVie Privacy Notice.
14.2We may suspend or end your access if you breach these Programme Terms or no longer meet the eligibility requirements.
14.3We will give you at least 30 days notice by email before the Programme closes. When it closes, Programme content will be withdrawn from the Partner Hub. Certificates already issued remain valid and available in your account.
15. Changes to these Programme Terms
15.1We may amend these Programme Terms from time to time. Any material change, particularly to the data shared with AbbVie or how it is used, will be notified to you by email and on the platform before it takes effect, and will be reviewed by AbbVie before publication.
16. Governing Law
16.1These Programme Terms are governed by the laws of England and Wales, and the courts of England and Wales have exclusive jurisdiction.
17. Contact
CliniLink Academy (CliniLink Ltd)
Registered Office: Stockport Pyramid, Yew Street, Stockport Trading Estate, Stockport, SK4 2JZ, United Kingdom
Company Number: 16243215
ICO Registration Number: ZB896601
Email: [email protected]
AbbVie adverse event reporting: [email protected]
We will acknowledge written enquiries within five working days.